21-46116387-G-T
Variant summary
Our verdict is Pathogenic. The variant received 10 ACMG points: 10P and 0B. PM1PM2PP3_StrongPP5_Moderate
The NM_001849.4(COL6A2):c.911G>T(p.Gly304Val) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★).
Frequency
Consequence
NM_001849.4 missense
Scores
Clinical Significance
Conservation
Publications
- collagen 6-related myopathyInheritance: AD, AR Classification: DEFINITIVE Submitted by: ClinGen
- Ullrich congenital muscular dystrophy 1BInheritance: AR, AD Classification: DEFINITIVE Submitted by: G2P
- Bethlem myopathy 1AInheritance: AD, AR Classification: STRONG Submitted by: Genomics England PanelApp
- Ullrich congenital muscular dystrophy 1AInheritance: AD, AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- Bethlem myopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Ullrich congenital muscular dystrophyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- myosclerosisInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 10 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_001849.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| COL6A2 | NM_001849.4 | MANE Select | c.911G>T | p.Gly304Val | missense | Exon 8 of 28 | NP_001840.3 | ||
| COL6A2 | NM_058174.3 | MANE Plus Clinical | c.911G>T | p.Gly304Val | missense | Exon 8 of 28 | NP_478054.2 | ||
| COL6A2 | NM_058175.3 | c.911G>T | p.Gly304Val | missense | Exon 8 of 28 | NP_478055.2 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| COL6A2 | ENST00000300527.9 | TSL:1 MANE Select | c.911G>T | p.Gly304Val | missense | Exon 8 of 28 | ENSP00000300527.4 | ||
| COL6A2 | ENST00000397763.6 | TSL:5 MANE Plus Clinical | c.911G>T | p.Gly304Val | missense | Exon 8 of 28 | ENSP00000380870.1 | ||
| COL6A2 | ENST00000409416.6 | TSL:5 | c.911G>T | p.Gly304Val | missense | Exon 7 of 27 | ENSP00000387115.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Bethlem myopathy 1A Pathogenic:1
This sequence change replaces glycine with valine at codon 304 of the COL6A2 protein (p.Gly304Val). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and valine. This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a COL6A2-related disease. In summary, this variant is a rare missense change that resides within the COL6A2 triple helix region. This evidence indicates that the variant is pathogenic, but additional data is needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Glycine residues within the triple helix region are crucial to maintain fibrillar collagens structure and stability (PMID: 7695699, 19344236). In the case of COL6A2, missense substitutions that affect glycine residues within the triplex helix domain have been reported in many patients affected with autosomal dominant collagen VI myopathy (PMID: 24038877).
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at